University of Michigan - Ann Arbor

- Mortality was significantly different among those with SIC score ≥ 4 (40.0% vs 64.2%, P = .029)

- Mortality was not significantly different for those with SIC score < 4 (29.0% vs 22.6%, P = .419)

- Overall mortality was not significantly different by group (30.3% vs 29.7%, P = .910).

- Odds ratios, confidence intervals can be found in table 4 in child node

Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score

- Among those given no anticoagulant, mortality increased as D-dimer levels increased

- Among treatment group, mortality stayed about the same

- “When D-dimer exceeding 3.0 μg/mL (6-fold of upper limit of normal, six ULN), ap- proximate 20% reduction in mortality with heparin treat was found (32.8% vs 52.4%, P = .017).” 

- Odds ratios, confidence intervals can be found in table 4 in child node

Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.

Tang, N, Bai, H, Chen, X, Gong, J, Li, D, Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18: 1094– 1099. https://doi.org/10.1111/jth.14817

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Table 4. from Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy [outcome differences by heparin treatment, SIC score, D-dimer levels]

Learn Before